How to Get Tirzepatide Prescribed: Cost, Insurance, and Access Guide

Knowing that tirzepatide injections can produce 20% average body weight reduction is one thing. Actually accessing the medication — getting a prescription, understanding the cost, navigating insurance coverage, and managing out-of-pocket expenses — is often where patients encounter the most friction. For many people, the biggest barrier to tirzepatide treatment is not medical eligibility; it is practical access.

This guide cuts through that friction. It covers exactly how to get tirzepatide prescribed, what tirzepatide costs with and without insurance, how to navigate the prior authorization process, what manufacturer savings programs are available, and the expanding landscape of telehealth access to GLP-1 medications — so that patients who are clinically appropriate candidates for tirzepatide can pursue it with clarity and confidence.

Am I Eligible for Tirzepatide?

Tirzepatide (Zepbound): FDA-approved for chronic weight management in adults with a BMI ≥30 kg/m² (obesity), or a BMI ≥27 kg/m² with at least one weight-related comorbidity — including hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea. It is also FDA-approved as Mounjaro for type 2 diabetes in adults and children aged 10 and older.

The eligibility criteria for tirzepatide are defined by the FDA’s approved indications — but understanding them in practical terms helps patients assess whether they qualify before investing time in the prescription process.

Eligibility Criteria for Weight Management (Zepbound)

You may be eligible for Zepbound (tirzepatide for weight loss) if you meet either of these BMI-based criteria:

• BMI ≥ 30 kg/m² — this corresponds to clinical obesity. For a person who is 5’6″ tall, this threshold is approximately 186 lbs; for someone 5’10”, approximately 209 lbs.
• BMI ≥ 27 kg/m² — this is the overweight threshold — plus at least one weight-related health condition. Qualifying conditions commonly include:
  • High blood pressure (hypertension)
  • High cholesterol or triglycerides (dyslipidemia)
  • Type 2 diabetes or pre-diabetes
  • Obstructive sleep apnea
  • Non-alcoholic fatty liver disease (NAFLD)
  • Cardiovascular disease or elevated cardiovascular risk

Eligibility Criteria for Type 2 Diabetes (Mounjaro)

If you have been diagnosed with type 2 diabetes, you may be eligible for Mounjaro as an adjunct to diet and exercise for glycemic control, regardless of BMI. Mounjaro is approved for adults and for children aged 10 and older. It is not indicated for type 1 diabetes.

Medical Contraindications

Even if you meet BMI eligibility criteria, certain medical conditions preclude tirzepatide use:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Known severe hypersensitivity to tirzepatide or its excipients
• Pregnancy (tirzepatide should be stopped at least 2 months before a planned pregnancy)
• Severe gastrointestinal disease

If you are unsure whether you qualify, the evaluation is straightforward — a brief clinical visit or telehealth consultation with a physician can assess your BMI, review your medical history for qualifying conditions or contraindications, and determine whether tirzepatide is an appropriate fit.

How to Get a Tirzepatide Prescription

Tirzepatide is a prescription-only medication — it cannot be purchased over the counter or accessed without a licensed prescriber’s order. Here is how to move through the prescription process effectively.

Step 1: Make an Appointment with a Qualified Provider

The first step is a clinical evaluation with a provider authorized to prescribe tirzepatide. Appropriate providers include:

• Primary care physicians (PCPs) — the most common starting point for tirzepatide prescriptions; most PCPs are now familiar with the drug and comfortable prescribing it for appropriate patients
• Endocrinologists — particularly appropriate for patients with type 2 diabetes or complex hormonal conditions
• Obesity medicine specialists — physicians who specialize in weight management and are expert in the nuances of GLP-1 class therapy
• Bariatric physicians — non-surgical weight management specialists at bariatric or metabolic health clinics
• Telehealth providers — see the section below for specific guidance on the growing telehealth pathway

Step 2: Prepare for Your Evaluation

To make your clinical visit as productive as possible, come prepared with the following:

• Your current height and weight (or access to a recent measurement)
• A list of current medications, supplements, and allergies
• Your medical history — particularly any diagnoses that may qualify as weight-related comorbidities (hypertension, sleep apnea, dyslipidemia, pre-diabetes, T2DM)
• Recent lab results if available (fasting glucose, HbA1c, lipid panel, thyroid function)
• A clear statement of your weight loss or glycemic management goals
• Questions about insurance coverage and cost — providers deal with these issues routinely and can often advise on prior authorization requirements

Step 3: Discuss Whether Tirzepatide Is Right for You

During the evaluation, your provider will assess your eligibility, review contraindications, discuss the clinical evidence for tirzepatide, and determine whether its benefits outweigh the risks and costs for your specific situation. If you are an appropriate candidate, the provider will write a prescription — typically for Zepbound if the primary indication is weight management, or Mounjaro if the primary indication is type 2 diabetes.

Step 4: Prescription Submission and Pharmacy Fulfillment

Tirzepatide is available at most major retail pharmacies and through specialty pharmacy networks. Your provider will submit the prescription electronically or by phone. Depending on your insurance plan, the pharmacy may need to run a prior authorization check before dispensing — which can take anywhere from a few hours to several weeks. Understanding the prior authorization process (covered in detail below) helps patients avoid unexpected delays.

Getting Tirzepatide Through Telehealth

The telehealth pathway for GLP-1 medications has expanded significantly since 2022 and represents one of the most convenient and accessible routes to tirzepatide for many patients, particularly those in areas with limited access to obesity medicine specialists or endocrinologists.

How Telehealth Prescribing for Tirzepatide Works

Numerous digital health platforms now offer online medical consultations for GLP-1 and GIP/GLP-1 weight management medications, including tirzepatide. The general process involves:

• Completing an intake questionnaire covering your medical history, current medications, weight history, and health goals
• A synchronous video consultation (or, in some states, asynchronous review) with a licensed physician or nurse practitioner
• If eligible, receiving an electronic prescription sent directly to a participating pharmacy
• Ongoing virtual follow-up visits for dose management and monitoring

Several dedicated obesity medicine telehealth platforms — including major providers that specialize specifically in GLP-1 medication management — have emerged to serve this market. When choosing a telehealth provider, patients should look for platforms that include physician (rather than nurse-only) oversight, offer ongoing follow-up care rather than just a one-time prescription, and have clear policies around insurance billing and cost transparency.

Important Telehealth Caveats

• Telehealth prescribing laws vary by state — in most states, a licensed provider can prescribe tirzepatide via telehealth, but specific requirements around state licensure and prescribing authority vary
• Insurance coverage through telehealth platforms may differ from in-person care; verify coverage before the consultation
• Be cautious of platforms that advertise tirzepatide without requiring a thorough medical evaluation — appropriate prescribing requires a genuine clinical assessment, not just a BMI check

How Much Does Tirzepatide Cost?

List Price Context: The cost of brand-name GLP-1 and GIP/GLP-1 medications reflects both the high cost of pharmaceutical development and the current limited availability of generics. The full list prices quoted below represent what patients would pay without any insurance, savings program, or discount — and are therefore the maximum cost scenario, not the typical patient experience.

The list price of tirzepatide in the United States varies by dose and package configuration, but generally falls in the range of $900 to $1,350 per month for Zepbound and comparable pricing for Mounjaro at full list price without insurance or discounts. These prices apply at major retail pharmacies when paying cash without any savings program.

Cost Breakdown by Dose (Approximate List Price, March 2026)

These are list prices, not the prices most patients actually pay. With commercial insurance coverage, the effective out-of-pocket cost for many patients ranges from a nominal co-pay to a few hundred dollars per month after manufacturer savings program application. Patients without any form of coverage or discount access are the minority who face the full list price — and even for those patients, several meaningful cost-reduction pathways exist.

Tirzepatide Insurance Coverage: What to Know

Coverage for tirzepatide varies substantially based on the insurance plan, the prescribed indication (diabetes vs. weight management), and the plan’s formulary status for each brand. Understanding the coverage landscape is essential to setting accurate cost expectations.

Commercial Insurance (Employer-Sponsored and Individual Market Plans)

The majority of major commercial insurance carriers in the United States cover at least one of the tirzepatide brand names — either Mounjaro (for type 2 diabetes) or Zepbound (for weight management) — on their formularies. Coverage for the diabetes indication (Mounjaro) is generally more consistently available than coverage for the weight management indication (Zepbound), as diabetes medications have historically received broader formulary inclusion than anti-obesity medications.

Even when tirzepatide appears on an insurance formulary, the following conditions commonly apply:

• Prior authorization: Most plans require a prior authorization (PA) for tirzepatide, meaning the prescribing physician must submit documentation to the insurance company demonstrating that the patient meets criteria before the plan will cover the drug. This is the most common source of access delays.
• Step therapy: Some plans require evidence that the patient has tried and failed one or more prior weight management medications or interventions before covering tirzepatide.
• BMI and comorbidity documentation: Insurance plans typically require physician documentation of the patient’s BMI and qualifying weight-related comorbidity to approve Zepbound coverage.
• Co-pays and co-insurance: Even with coverage, patient cost-sharing (co-pays or co-insurance) for tirzepatide typically ranges from $25 to $250+ per month depending on plan design and formulary tier.

ACA Marketplace Plans

Coverage for anti-obesity medications on ACA marketplace plans varies significantly by plan and state. Bronze and Silver tier plans often have higher cost-sharing requirements for specialty medications, which may make tirzepatide expensive even when technically covered. Patients on ACA plans should review the specific formulary and cost-sharing structure of their plan before initiating the prescription process.

Navigating Prior Authorization for Tirzepatide

Prior authorization (PA) is a process by which your insurance company requires your prescribing physician to submit clinical documentation before agreeing to cover a prescribed medication. It is one of the most common barriers to timely tirzepatide access and the most important process for patients and providers to understand and navigate effectively.

What Does a Prior Authorization for Tirzepatide Require?

PA requirements vary by insurance plan, but commonly include documentation of:

• The patient’s current BMI (for Zepbound) or HbA1c/diabetes diagnosis (for Mounjaro)
• The presence of at least one qualifying weight-related comorbidity (for Zepbound at BMI ≥27)
• Evidence that the patient has been counseled on or has attempted lifestyle modifications (diet and exercise)
• The absence of contraindications (personal or family history of MTC, MEN 2)
• Prescriber attestation that the medication is being used as an adjunct to lifestyle modification

The PA Submission Process

In practice, the PA process typically works as follows:

• Your provider submits a PA request to your insurance company, either through an electronic prior authorization (ePA) portal or by fax
• The insurance company reviews the documentation and responds — initial reviews typically take 1 to 5 business days, though urgent reviews can be completed more quickly
• The plan approves, denies, or requests additional information
• If denied, the physician can initiate a peer-to-peer review (a direct conversation between your prescribing physician and a physician reviewer from the insurance company) — this step resolves a significant proportion of initial denials
• If peer-to-peer review is unsuccessful, a formal appeal can be filed — and if that fails, an external review by an independent body can be requested

Tips for Improving Prior Authorization Success

• Ensure the PA request is comprehensive on the first submission. Many denials result from incomplete documentation rather than genuine ineligibility. Ask your provider’s office to confirm that all required fields are completed before submission.
• Request a peer-to-peer review promptly after any denial. Peer-to-peer conversations between physicians frequently overturn initial administrative denials and are often the fastest path to resolution.
• Document all qualifying comorbidities in detail. A BP reading of 138/88 is hypertension and constitutes a qualifying comorbidity — make sure it is explicitly documented in the PA request.
• Ask your provider’s office about prior authorization support services. Many large clinics and telehealth platforms have dedicated PA specialists who manage this process on patients’ behalf, significantly increasing approval rates and reducing wait times.

Manufacturer Savings Programs and Patient Assistance

Eli Lilly — the manufacturer of both Mounjaro and Zepbound — offers savings programs designed to reduce out-of-pocket costs for patients who are commercially insured or who are paying out of pocket. These programs are separate from insurance and can be applied on top of insurance co-pays or used independently.

The Zepbound Savings Card

Eli Lilly offers a savings card program for Zepbound that allows eligible commercially insured patients to pay a reduced co-pay per month, subject to a monthly and annual program cap. Specific terms of savings card programs change periodically — patients should visit the official Zepbound.com website or call Lilly’s savings program phone number for the most current terms.

General eligibility requirements for manufacturer savings programs typically include:

• Residing in the United States and being 18 years of age or older
• Having commercial insurance that covers Zepbound or Mounjaro (savings cards typically do not apply to patients covered by government programs like Medicare, Medicaid, VA, or TRICARE)
• Not being enrolled in any state or federal government insurance program

Mounjaro Savings Card

The Mounjaro savings card operates on similar terms, targeting commercially insured patients with type 2 diabetes who are prescribed Mounjaro. As with Zepbound, specific terms are subject to change and should be confirmed at Mounjaro.com or through Lilly’s patient assistance phone line.

Lilly Cares Patient Assistance Program

For patients who are uninsured or underinsured and who meet income eligibility criteria, Eli Lilly’s Lilly Cares Foundation offers a patient assistance program that can provide Mounjaro or Zepbound at reduced or no cost. Patients can apply through LillyCares.com and will need to provide documentation of income and insurance status.

GoodRx and Pharmacy Discount Programs

GoodRx and similar pharmacy discount platforms offer discounted pricing on many brand-name medications, though savings on high-cost specialty drugs like tirzepatide are typically more modest than on generic medications. It is always worth checking GoodRx pricing at multiple local pharmacies, as prices can vary significantly between pharmacies in the same geographic area. GoodRx discounts cannot be combined with insurance but can be used as an alternative to insurance in some cost scenarios.

Tirzepatide and Medicare

Medicare coverage for tirzepatide is one of the most common sources of confusion and frustration for eligible patients. Here is the current status as of early 2026:

Coverage for Diabetes Indication (Mounjaro)

Medicare Part D plans are required to cover antidiabetic medications, and Mounjaro — as an FDA-approved type 2 diabetes medication — is covered by many Medicare Part D plans. Coverage, co-pay tier, and prior authorization requirements vary by specific plan. Patients with Medicare who have type 2 diabetes should check their specific Part D plan’s formulary to confirm Mounjaro coverage and cost-sharing.

Coverage for Weight Management Indication (Zepbound)

Historically, Medicare was prohibited by statute from covering anti-obesity medications under Part D, which excluded GLP-1 drugs when prescribed for weight loss. However, this policy landscape is actively evolving. The Treat and Reduce Obesity Act (TROA) has been repeatedly reintroduced in Congress, and CMS (the Centers for Medicare & Medicaid Services) finalized rules in 2025 allowing Medicare Part D coverage for anti-obesity medications — including Zepbound — for patients who meet clinical criteria, effective 2026.

Patients with Medicare who are interested in tirzepatide for weight management should verify their current Part D plan’s coverage for Zepbound and consult with a Medicare plan specialist or their healthcare provider for the most current coverage guidance, as implementation timelines and plan-specific formulary decisions continue to evolve.

Medicare Savings Programs

Manufacturer savings cards (like the Zepbound and Mounjaro savings cards) are generally not available to Medicare beneficiaries due to federal anti-kickback statutes. Medicare patients who cannot afford their out-of-pocket costs for tirzepatide should explore Medicare Savings Programs, the Low Income Subsidy (Extra Help) program, and Lilly’s LillyCares patient assistance program, which may provide assistance regardless of insurance status based on income criteria.

What to Do If You Have No Insurance Coverage for Tirzepatide

Patients without insurance coverage for tirzepatide — whether due to no coverage at all, a plan that excludes anti-obesity medications, or Medicare pre-coverage limitations — still have several pathways to explore before concluding the medication is inaccessible.

Option 1: Apply for Manufacturer Patient Assistance

If you are uninsured or underinsured and meet income eligibility criteria, the Lilly Cares Foundation patient assistance program can provide Mounjaro or Zepbound at no or reduced cost. Apply at LillyCares.com. Income documentation will be required.

Option 2: Explore State Pharmaceutical Assistance Programs

Many states operate pharmaceutical assistance programs that can help residents access expensive medications at reduced cost. Eligibility, covered medications, and program scope vary by state. Your pharmacist, state health department, or NeedyMeds.org can provide guidance on available programs in your state.

Option 3: Clinical Trials

Ongoing clinical trials studying tirzepatide for new indications may provide access to the medication at no cost to eligible participants. ClinicalTrials.gov lists all active trials and eligibility criteria. Participation typically requires commitment to trial visits and protocols, but can provide high-quality access and monitoring.

Option 4: Appeal Insurance Denials Aggressively

If your insurance has denied coverage for tirzepatide, the denial is not necessarily final. The appeals process — including peer-to-peer review by your physician, formal administrative appeal, and external independent review — resolves a meaningful proportion of initial denials. Work with your provider’s office to pursue appeals, and consider requesting a peer-to-peer review at the earliest stage available.

Option 5: Explore Whether the Other Brand Name Applies

If your plan does not cover Zepbound (weight management) but does cover Mounjaro (type 2 diabetes), and you have a qualifying diabetes diagnosis, your provider may prescribe Mounjaro under the diabetes indication. This is a legitimate clinical decision when both the diabetes and weight management indications are clinically relevant for a given patient — and not all plans that deny Zepbound also deny Mounjaro.

Compounded Tirzepatide: The Current Status

Important Update as of October 2024: Tirzepatide was removed from the FDA drug shortage list in October 2024. Following this removal, the FDA stated that compounding pharmacies may no longer legally produce compounded versions of tirzepatide under shortage exemptions. Eli Lilly’s branded products — Mounjaro and Zepbound — are now widely available through standard pharmacy channels.

During the period of high demand and supply constraints following tirzepatide’s initial approval, many patients accessed compounded tirzepatide through compounding pharmacies — a practice that was temporarily permitted under FDA shortage provisions. That regulatory window has now closed.

Why the FDA Ended Compounded Tirzepatide Permissions

Compounding pharmacies are permitted by the FDA to prepare medications that are on the drug shortage list, on the basis that the clinical need for the drug cannot be met by commercially available supply. When tirzepatide was removed from the shortage list — reflecting Eli Lilly’s expanded manufacturing capacity and widespread commercial availability — the legal basis for compounding exemptions was eliminated.

The FDA has taken enforcement action against compounding pharmacies that continued producing tirzepatide after the shortage designation was removed. Patients who obtained compounded tirzepatide prior to this change should discuss transition to the FDA-approved branded product with their healthcare provider.

Why Compounded Tirzepatide Should Be Avoided

Beyond the current regulatory status, compounded medications carry inherent quality and safety risks that FDA-approved products do not:

• Compounded products are not reviewed by the FDA for safety, purity, potency, or efficacy
• Quality control standards at compounding pharmacies vary significantly
• Dosing accuracy in compounded preparations has been questioned in independent analyses
• Several compounded GLP-1 products have contained incorrect active ingredients or inactive compound forms
• Insurance plans do not cover compounded medications — patients pay entirely out of pocket

Patients and clinicians are strongly advised to use only FDA-approved Mounjaro or Zepbound, obtained from licensed pharmacies dispensing Eli Lilly’s commercially manufactured product.

Frequently Asked Questions

How do I ask my doctor for tirzepatide?

Be direct and specific. Tell your doctor you are interested in discussing tirzepatide (Zepbound or Mounjaro) as a treatment option for weight management or type 2 diabetes. Mention your current BMI or weight-related health conditions, and ask whether you meet the FDA’s approved eligibility criteria. Most physicians are now familiar with the clinical evidence for tirzepatide and will have an informed discussion about whether it is appropriate for you.

How long does it take to get a tirzepatide prescription?

If you are seeing an in-network provider with a short appointment availability and your insurance processes the prior authorization quickly, you may have your first prescription in hand within one to two weeks of your initial consultation. More commonly, the prior authorization process adds two to four weeks to the timeline, particularly if additional documentation or peer-to-peer review is required.

Can I get tirzepatide if I don’t have insurance?

Yes, through several pathways. The Lilly Cares patient assistance program provides medication at no or reduced cost to income-eligible uninsured patients. Some patients use GoodRx or similar discount programs. Others may access tirzepatide through clinical trials at no charge. Without any assistance programs, the cash price is $900 to $1,350 per month — affordable primarily for patients who qualify for patient assistance or can access employer-based health savings accounts (HSAs or FSAs).

Does prior authorization for tirzepatide always take a long time?

Not always. Electronic prior authorization (ePA) systems, which many large prescribing practices now use, can receive responses from insurance companies within hours to a day or two. Complex cases — or those requiring peer-to-peer review — take longer. Working with a provider’s office that has experienced PA support staff is the single most reliable predictor of a faster, more successful prior authorization process.

Is tirzepatide the same price at all pharmacies?

No. List prices for tirzepatide vary between pharmacies, and GoodRx discounted prices vary as well. Patients paying out of pocket should compare prices across multiple pharmacies — including both retail chains (CVS, Walgreens, Rite Aid) and mail-order pharmacies — before filling. Savings of $100 to $300 per month between pharmacies for the same medication are not uncommon.

What if my insurance denies tirzepatide coverage?

An initial denial is not final. Request a peer-to-peer review immediately — this step, in which your prescribing physician speaks directly with the insurance company’s reviewing physician, resolves a significant proportion of denials. If peer-to-peer review fails, file a formal appeal. If the formal appeal fails, request an external independent review. Throughout this process, apply for the Lilly manufacturer savings card as a bridge — it may reduce your cost substantially while the appeal is in progress.

Conclusion: Accessing Tirzepatide Is a Process — Start It with Clear Information

Getting a tirzepatide prescription is not a simple one-step transaction — it is a multi-stage process involving clinical evaluation, insurance navigation, and potentially appeals and savings program applications. But for patients who are clinically appropriate candidates, the barriers are navigable, and the clinical payoff is substantial.

The most important first step is the most straightforward one: a conversation with a qualified healthcare provider who can evaluate your eligibility, initiate the prescription process, and help you navigate the prior authorization landscape. Whether you pursue that conversation with your primary care physician, an endocrinologist, an obesity medicine specialist, or a telehealth platform, having that first clinical interaction is the gateway to everything that follows.

Tirzepatide’s clinical results — 20% average body weight reduction, unprecedented HbA1c control, potential cardiovascular risk reduction — represent outcomes that are genuinely transformative for eligible patients. The work of accessing the medication is worth doing. Approach it systematically, understand the process, advocate for yourself through the prior authorization and appeals pathway, and work with providers and programs that specialize in making that process as smooth as possible.